2022 - Research.com Best Female Scientist Award
2017 - Member of the National Academy of Medicine (NAM)
Member of the Association of American Physicians
Her primary areas of study are Immunology, Internal medicine, Melanoma, Cancer and Oncology. Her work deals with themes such as Gastroenterology and Surgery, which intersect with Internal medicine. Her study in Melanoma is interdisciplinary in nature, drawing from both Interleukin 2 and Renal cell carcinoma.
Her study in Immunotherapy and Melanoma Vaccine is done as part of Cancer. Suzanne L. Topalian has included themes like Pembrolizumab, Progressive disease, Pancreatic cancer and Pathology in her Oncology study. Her work carried out in the field of Lung cancer brings together such families of science as Colorectal cancer, Prostate cancer and Biopsy.
Suzanne L. Topalian focuses on Immunology, Melanoma, Internal medicine, Cancer research and Immunotherapy. Her research ties Cancer and Immunology together. As part of one scientific family, Suzanne L. Topalian deals mainly with the area of Melanoma, narrowing it down to issues related to the Tumor-infiltrating lymphocytes, and often Cytokine secretion and Cyclophosphamide.
Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Surgery and Oncology. The various areas that Suzanne L. Topalian examines in her Cancer research study include CD20, MHC class I, FOXP3 and Cancer immunotherapy. The Immunotherapy study combines topics in areas such as T lymphocyte, Adoptive cell transfer, Metastasis, Interleukin 2 and Lymphokine-activated killer cell.
Her primary areas of investigation include Cancer research, Oncology, Internal medicine, Immunotherapy and Nivolumab. Her Cancer research research includes themes of Blockade and Immune system, FOXP3. Her Immune system study integrates concerns from other disciplines, such as Antigen and B cell.
Her Oncology research is multidisciplinary, relying on both Stage, Biopsy, Pembrolizumab and Autopsy. Her study on Immunotherapy is covered under Cancer. Her Nivolumab research integrates issues from Neoadjuvant therapy, Major Pathologic Response, Clinical trial, Carcinoma and Lung cancer.
Her scientific interests lie mostly in Nivolumab, Internal medicine, Oncology, Cancer research and Carcinoma. Her studies deal with areas such as Clinical trial and Melanoma as well as Nivolumab. Her research in Melanoma intersects with topics in Odds ratio, Progressive disease and Renal cell carcinoma.
She is studying Progression-free survival, which is a component of Internal medicine. Her Cancer research research incorporates themes from Merkel cell carcinoma and Immune system. Her Ipilimumab study combines topics in areas such as Immune checkpoint and Blockade.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger.
The New England Journal of Medicine (2012)
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu.
The New England Journal of Medicine (2012)
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu.
The New England Journal of Medicine (2003)
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang.
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes.
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly.
Journal of Clinical Oncology (2010)
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
S A Rosenberg;B S Packard;P M Aebersold;D Solomon.
The New England Journal of Medicine (1988)
Immune checkpoint blockade: a common denominator approach to cancer therapy
Suzanne L. Topalian;Charles G. Drake;Drew M. Pardoll.
Cancer Cell (2015)
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu.
Nature Medicine (1998)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger.
Journal of Clinical Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: